211 related articles for article (PubMed ID: 26592504)
1. Uterine adenosarcomas are mesenchymal neoplasms.
Piscuoglio S; Burke KA; Ng CK; Papanastasiou AD; Geyer FC; Macedo GS; Martelotto LG; de Bruijn I; De Filippo MR; Schultheis AM; Ioris RA; Levine DA; Soslow RA; Rubin BP; Reis-Filho JS; Weigelt B
J Pathol; 2016 Feb; 238(3):381-8. PubMed ID: 26592504
[TBL] [Abstract][Full Text] [Related]
2. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
3. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.
Momeni Boroujeni A; Kertowidjojo E; Wu X; Soslow RA; Chiang S; Da Silva EM; Weigelt B; Chui MH
Mod Pathol; 2022 Nov; 35(11):1684-1694. PubMed ID: 36138078
[TBL] [Abstract][Full Text] [Related]
4. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.
Geyer FC; Burke KA; Piscuoglio S; Ng CKY; Papanastasiou AD; Marchiò C; Selenica P; Edelweiss M; Murray MP; Brogi E; Soslow RA; Rubin BP; Norton L; Reis-Filho JS; Weigelt B
Mol Oncol; 2017 Aug; 11(8):913-926. PubMed ID: 28267263
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
[TBL] [Abstract][Full Text] [Related]
7. Uterine Adenosarcoma.
Pinto A; Howitt B
Arch Pathol Lab Med; 2016 Mar; 140(3):286-90. PubMed ID: 26927725
[TBL] [Abstract][Full Text] [Related]
8. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.
Lee JC; Lu TP; Changou CA; Liang CW; Huang HN; Lauria A; Huang HY; Lin CY; Chiang YC; Davidson B; Lin MC; Kuo KT
Mod Pathol; 2016 Sep; 29(9):1070-82. PubMed ID: 27255164
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma.
Yoon JY; de Kock L; Stewart CJR; McCluggage WG; Foulkes WD; Clarke BA; Rouzbahman M
Cancer Treat Res Commun; 2021; 27():100363. PubMed ID: 33838572
[TBL] [Abstract][Full Text] [Related]
10. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
[TBL] [Abstract][Full Text] [Related]
11. Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma.
de Kock L; Yoon JY; Apellaniz-Ruiz M; Pelletier D; McCluggage WG; Stewart CJR; Dickson BC; Rouzbahman M; Clarke BA; Foulkes WD
Mod Pathol; 2020 Jun; 33(6):1207-1219. PubMed ID: 31900434
[TBL] [Abstract][Full Text] [Related]
12. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.
Soslow RA; Ali A; Oliva E
Am J Surg Pathol; 2008 Jul; 32(7):1013-21. PubMed ID: 18469708
[TBL] [Abstract][Full Text] [Related]
13. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma.
Swisher EM; Gown AM; Skelly M; Ek M; Tamimi HK; Cain JM; Greer BE; Muntz HG; Goff BA
Gynecol Oncol; 1996 Jan; 60(1):81-8. PubMed ID: 8557233
[TBL] [Abstract][Full Text] [Related]
14. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive screening for MED12 mutations in gynaecological mesenchymal tumours identified morphologically distinctive mixed epithelial and stromal tumours.
Yuan CT; Huang WC; Lee CH; Lin MC; Lee CH; Kao YC; Huang HY; Kuo KT; Lee JC
Histopathology; 2017 May; 70(6):954-965. PubMed ID: 28002623
[TBL] [Abstract][Full Text] [Related]
16. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
17. Targeted genomic analysis of Müllerian adenosarcoma.
Howitt BE; Sholl LM; Dal Cin P; Jia Y; Yuan L; MacConaill L; Lindeman N; Kuo F; Garcia E; Nucci MR; Quade BJ
J Pathol; 2015 Jan; 235(1):37-49. PubMed ID: 25231023
[TBL] [Abstract][Full Text] [Related]
18. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
19. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of CD10 antigen in uterine adenosarcoma.
Amant F; Steenkiste E; Schurmans K; Verbist L; Abeler VM; Tulunay G; de Jonge E; Massuger L; Moerman P; Vergote I
Int J Gynecol Cancer; 2004; 14(6):1118-21. PubMed ID: 15571618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]